Also known as Sprycel
Dasatinib, previously known as BMS-354825, is a cancer drug produced by Bristol-Myers Squibb and sold under the trade name Sprycel. Dasatinib is an oral multi- BCR/ABL and Src family tyrosine kinase inhibitor approved for first line use in patients with chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is being evaluated for use in numerous other cancers, including advanced prostate cancer.Source: Wikipedia
Estimated Total Cost: $5715.17 for an average of 28 days supply
Patients are most commonly prescribed dasatinib to treat rabies, blastomycosis, west nile virus, and pick disease.
Patients taking dasatinib most commonly experience side effects like thrombocytopenia, anemia, and headache.
|Shortness of breath|
|Gastrointestinal hemorrhage (GI Bleeding)|
|High blood pressure|